177Lu-PSMA-VG01
Phase 1Radiopharmaceutical
177Lu-PSMA-VG01 is one of 9 therapeutic programs targeting Metastatic Castration-resistant Prostate Cancer, mCRPC. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
8 competitors in Metastatic Castration-Resistant Prostate Cancer, Mcrpc
#DrugCompanyPhaseTrials
1Xtandi
AstellasPhase 1
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 1
AAA617
NovartisPhase 2
Xaluritamig
AmgenPhase 1
Libtayo
RegeneronPreclinical
68ga-PSMA-11
UUniversity of Texas Southwestern Medical Center
Phase 2
Mervometostat (PF-06821497)
PfizerPhase 1
177Lu-PSMA-VG01
VVitsGen Therapeutics Inc.
Phase 1
REGN5678
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 177Lu-PSMA-VG01. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical
- Highest Phase
- Phase 1[1]
- Company
- VVitsGen Therapeutics Inc.